Bitcoin price today: hits record high over $124k on rate cut bets, corporate cheer
STOUGHTON, Mass. - Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a diversified biopharmaceutical company with a market capitalization of $928 million and impressive gross profit margins of 87%, today announced significant changes to its Board of Directors and executive team. According to InvestingPro analysis, the company maintains a "GREAT" financial health score, positioning it well for future growth. Gino Santini is set to become the new Chairman of the Board, succeeding Michael Heffernan, the company’s founder, who along with Gwen A. Melincoff, will retire from the board at the upcoming Annual General Meeting on May 15, 2025. Dr. Carlos Paya has been nominated to join the board, subject to shareholder approval at the AGM.
These board changes follow the recent addition of Nancy S. Lurker in February 2025 and are part of the company’s strategy for board refreshment and succession planning. The outgoing Chairman, Heffernan, expressed confidence in the company’s future success and its dedication to patients and community. The company’s strong positioning is reflected in its attractive valuation metrics, with current market analysis suggesting the stock is undervalued.
In addition to the board updates, Collegium has appointed three new executives to its leadership team. David Dieter joins as Executive Vice President, General Counsel; Jane Gonnerman as Executive Vice President, Strategy and Corporate Development; and Dean J. Patras as Chief People Officer. President and CEO Vikram Karnani welcomed the new members, highlighting their expertise and track records as valuable assets for the company’s next growth phase.
Dr. Paya brings over 30 years of experience as a physician-scientist and biopharmaceutical executive, with a background that includes leadership roles at Immune Design Corp., Elan Pharmaceuticals, and Eli Lilly. Dieter, Gonnerman, and Patras all come from significant positions in other pharmaceutical companies, bringing a wealth of experience in legal, corporate strategy, and human resources, respectively.
Collegium is focused on expanding its portfolio, with Jornay PM for ADHD treatment as a lead growth driver, and aims to strategically deploy capital to create shareholder value. With revenue growth of 11.4% in the last twelve months and positive analyst revisions for upcoming earnings, the company shows promising momentum. The company’s headquarters are in Stoughton, Massachusetts, and it is committed to improving the lives of people with serious medical conditions. For deeper insights into Collegium’s growth potential and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
The information in this article is based on a press release statement from Collegium Pharmaceutical.
In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.75, compared to the forecast of $1.66. The company also exceeded revenue projections, posting $181.9 million against the anticipated $179.48 million. This performance reflects strong growth in their ADHD and pain management portfolios. Additionally, Collegium Pharmaceuticals announced strategic changes in its board of directors and executive team. Dr. Carlos Paya has been nominated for election, while long-standing board members Michael Heffernan and Gwen Melincoff will retire. On the executive front, David Dieter has been appointed as Executive Vice President and General Counsel. These leadership changes are part of Collegium’s commitment to governance and management excellence. Looking forward, the company projects net product revenue between $735 million and $750 million for 2025, with adjusted EBITDA expected to grow by over 10%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.